Fujirebio and Sysmex Announce Bolstered Global Immunoassay Partnership; Deal Will Look to Leverage Combined Strengths

Fujirebio Holdings, Inc. and Sysmex Corporation have announced that the companies have further strengthened their collaboration in immunoassays. The new business collaboration encompasses areas such as research and development, production, clinical development, and sales-marketing and the companies believe that through their partnership they can both expand their respective immunoassay portfolios on a global basis.

Sysmex has been focused on expanding its immunochemistry business across the world, particularly in the U.S. and Europe. Recent initiatives include the development of unique tests, such as reagents to detect amyloid beta (Aβ) accumulation in the brain, a key factor in Alzheimer’s disease diagnosis. Fujirebio, also has a well-established history in immunoassay tests and boasts a diverse range of reagent raw materials and product portfolios. Since 2020, Fujirebio, along with its subsidiaries, has been diligently working on dedicated reagents for Sysmex’s Automated Immunoassay System HISCL™-Series as part of this strategic endeavor.

The new agreement will deepen their current collaboration and stems from the shared belief that leveraging their respective expertise and immunoassay strengths will significantly expedite their global reach and contribute to the advancement of the company’s immunoassay portfolio. The companies are actively exploring various avenues of cooperation, ranging from research and development to production, clinical development, and sales-marketing, with plans to begin executing these initiatives by the end of March 2024.